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Abstract Our objective was to describe: 1) physicians’
knowledge of whether genetic counseling is provided to
parents of newborns with sickle cell trait (SCT) or who
are cystic fibrosis carriers (CFC), and 2) the prevalence
of genetic counseling provided by primary care physi-
cians. We conducted a cross-sectional descriptive survey
of 600 randomly-sampled Michigan-based pediatricians
and family physicians, assessing physician knowledge of
where and whether genetic counseling is received by
parents whose newborns are carriers. Chi-squared testing
determined associations between genetic counseling loca-
tion and physician demographic characteristics. Our re-
sponse rate was 62 %: 298 (84 %) provided infant well
care (183 pediatricians, 115 family physicians). Most
respondents were non-Hispanic White (65 %). Virtually
all physicians believed parents whose newborns are car-
riers of either SCT or CFC should receive some genetic
counseling (from the physician and/or another source),
yet 20 % reported that parents of newborns with SCT
did not receive counseling. Parents of infants with CFC
received more counseling overall (92 % vs. 80 %; p<
0.01) and were counseled more frequently by genetic
counselors or specialty centers than parents of newborns
with SCT (85 % vs. 60 %; p<0.01). Although physicians
agreed that parents whose newborns are carriers should
receive genetic counseling, fewer parents of newborns
with SCT than with CFC received counseling from any
source. This finding strongly suggests the need for fur-
ther education and investigation of this apparent health
disparity.
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Abbreviations
SCD Sickle cell disease
CF Cystic fibrosis
SCT Sickle cell trait
CFC Cystic fibrosis carrier
NCAA National Collegiate Athletic Association
PCP Primary care physician
Introduction
Sickle cell anemia/disease (SCD) and cystic fibrosis (CF)
are the most common life-shortening, childhood-onset
inherited disorders in the United States (Centers for Disease
Control and Prevention 2004). All 50 states screen
newborns for both conditions, although cystic fibrosis
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screening is a new addition for most (National Newborn
Screening and Genetics Resource Center 2010). The state of
Michigan initiated newborn screening for CF in 2007, while
newborn screening for SCD began 20 years earlier in 1987
(Kleyn et al. 2011; Kleyn et al. 2009a). Unlike most other
newborn screening tests, tests for sickle cell anemia and
cystic fibrosis also detect infants who are carriers of sickle
cell disease (sickle cell trait, SCT) or cystic fibrosis (cystic
fibrosis carriers, CFC).
For the parents whose newborns are carriers of either
SCT or CF, genetic counseling is helpful to assess the
parents’ risk of having affected children or children who
are carriers in future pregnancies. The risk of having an
affected child can be as high as 25 % if both parents are
carriers. For the newborn, the health implications of being a
carrier of one of these diseases are very different. CF carriers
have no increased personal health risk, while health risks do
exist for persons with SCT. Individuals with SCT risk de-
veloping hematuria and a decreased ability to concentrate
urine beginning in adolescence and worsening with age (Le
Gallais et al. 1996; Mitchell 2007). Research also supports
an increased risk of sudden death or serious illness under
conditions of severe hypoxia, extreme physical exertion or
significant dehydration (American College of Medical Ge-
netics 2006; Kark et al. 1987; Le Gallais et al. 1996; Mitch-
ell 2007).
The results received by the primary care physician
are also different for the two newborn screening tests.
In nearly all cases, SCT is identified on the initial
newborn screen without the need for further testing. In
contrast, the positive result on the initial newborn
screening test for CF does not differentiate between
those with the disease and carriers. Further testing (usu-
ally a sweat test) is required to separate CF carriers
from children who actually have the disease. However,
the sweat test can be ordered and interpreted by a
primary care physician without referral to a specialist.
Purpose of the Present Study
Guidelines from the American Academy of Pediatrics and
the American College of Medical Genetics recommend that
parents whose newborns are carriers of SCT receive genetic
counseling. Consultation with a CF specialist is recommen-
ded for all those whose newborn screens are positive for CF
(American College of Medical Genetics 2006; American
College of Medical Genetics 2010; National Heart Lung
and Blood Institute; National Institutes of Health 2002).
Since genetic counseling requires more time than is gener-
ally available during a routine newborn visit in the primary
care physician’s office, we were interested in whether physi-
cians provided counseling in their office and/or knew that
parents had received counseling elsewhere. We were also
interested in determining whether there were any differences
between the two carrier states in physician provision and/or
knowledge of parental counseling. Our prior work demon-
strated that, despite the recommendations, primary care
physicians who provide well care for newborns are signifi-
cantly less likely to endorse a need for genetic counseling
for parents of infants with SCT than for parents of infants
with CFC (Kemper et al. 2006).
Methods
Sampling Frame
For this cross-sectional descriptive study, we requested the
names and office addresses of all the self-identified pedia-
tricians and family physicians in the state of Michigan from
the American Medical Association’s (AMA) Physician Mas-
terfile. According to the AMA (2012), “the Physician Mas-
terfile includes current and historical data for more than one
million residents and physicians and approximately 82,000
students in the United States,” regardless of AMA member-
ship. We requested that the list include only allopathic and
osteopathic physicians, practicing office-based, direct pa-
tient care, and whose board certification and self-reported
primary specialty were either pediatrics or family medicine
and exclude those who reported a secondary specialty or
sub-board, resident physicians, physicians practicing at a
military, prison, or federal facility, and physicians 70 years
of age or older. We used a random number table to select a
sample of 300 pediatricians and 300 family physicians from
this list. While the incidence of cystic fibrosis is evenly
distributed throughout the state, the incidence of sickle cell
anemia is correlated with the proportion of African Ameri-
cans living in a given area. To ensure an adequate represen-
tation of physicians who had patients with SCD, SCT, CF,
and CFC in their practices, we allocated half of our surveys
to the six counties with the highest populations of African
Americans.
Development of Survey Instrument and Survey Contents
We modified questions from our prior study about sickle cell
anemia and cystic fibrosis,(Kemper et al. 2006) adding
questions about the provision and location of genetic
counseling for parents of newborns with SCT and CFC.
The two-page survey was tested for acceptance and feasi-
bility in a population of office-based pediatricians and fam-
ily physicians who delivered primary care to infants.
The fielded survey consisted of 28 questions covering the
following areas:
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& Physician experience in providing well care for children
with SCT, CFC, SCD, or CF.
& Physician beliefs concerning whether and when parents
of newborns with SCT or CFC should be informed of
their child’s carrier status (“never,” “in the newborn
period,” or “sometime after the newborn period”).
& Physician knowledge of whether parents of newborns in
their practice with SCT or CFC received genetic
counseling [“Do the parents of sickle cell carrier (cystic
fibrosis carrier) newborns in your practice usually re-
ceive genetic counseling?”].
& If the respondent physician answered yes to the previous
question, they were asked to list all locations where
parents received counseling (in the primary care physi-
cian’s office, medical geneticist/genetic counselor office,
specialty center, or other locations).
& Physicians who responded that parents of newborn car-
riers in their practice did not receive counseling were
asked their reason(s) why counseling was not given.
Response options were the following: “No genetic coun-
selors available,” “I do not recommend it, “Parents do
not want it,” or “Other.”
& Demographic questions included physician age, race,
years in practice, practice location (urban, suburban,
rural), and approximate racial/ethnic composition of pa-
tient population.
Survey Administration
The initial mailing in November of 2008 contained the
survey, a cover letter describing the study that served as
the consent document, a small monetary incentive, and a
stamped, self-addressed business reply envelope for return
of the survey. Surveys were identified by number only.
Respondents were asked not to put their names on the
surveys to assure anonymity. Non-respondents received
two additional mailings at three-week intervals containing
a cover letter, the survey and a reply envelope. The com-
pleted and returned survey was viewed as the physician’s
consent to participate in the study. The University of Mich-
igan Medical School Institutional Review Board approved
the study.
Data Analyses
Surveys from physicians who did not provide care to chil-
dren less than 1 year of age were excluded. Descriptive
statistics were calculated for all survey items. Outcome
variables were physician report as to whether parents re-
ceived genetic counseling (yes/no); location(s) of all sources
of counseling or reasons parents do not receive counseling.
Predictor variables were respondent demographic and
practice characteristics. Using chi-square testing, we deter-
mined bivariate associations between outcome and predictor
variables. We also used chi-square testing to determine
whether there were significant differences in outcome vari-
ables between the two carrier states.
Respondents used U.S. Census categories to identify their
race(s). We categorized race as White (only White selected),
African American (only African American selected), Other
(single racial category that was neither White nor African
American), and Multi-racial (more than one racial category).
Due to small numbers, we did not analyze Hispanics separate-
ly. We considered a p-value of<0.05 as statistically signifi-
cant. All analyses were conducted in SAS (version 9.1).
Results
Of the 600 surveysmailed, 28 were undeliverable.We received
356 completed surveys (response rate 62%). The response rate
differed by specialty: 70 % of pediatricians and 56% of family
physicians returned a completed survey. We then excluded the
surveys of those who did not provide care to infants younger
than one-year of age. We were left with 298 surveys (84 % of
responders): 183 pediatricians and 115 family physicians. We
report the results of those 298 surveys herein.
Respondents had been in practice an average of 15 years,
with less than 20 % of the responding physicians practicing
more than 25 years. Average physician age was 46.5. Most
were White and only 8 % had a patient panel that was
mostly African American (Table 1). Pediatricians reported
significantly greater experience than family physicians in
providing well care for both children with SCD and CF and
carriers of either disease. Regardless of specialty, physicians
reported greater experience with well care for children with
SCD than for children with CF (Table 1). We asked respond-
ents to answer about the genetic counseling received by
parents of newborn carriers in their practice, rather than just
their own panel of patients, so we included the responses of
physicians who reported no personal experience providing
well care for affected children or children who are carriers.
More than 95 % of physicians stated that parents whose
newborns are carriers of either condition should be informed
of their child’s status in the newborn period and receive
genetic counseling at that time. However, carrier state-
specific differences were noted in whether counseling actu-
ally occurred and where counseling was provided.
Receipt and Location of Genetic Counseling (Table 2)
Most physicians reported that parents whose newborns are
carriers of either SCT or CFC received genetic counseling.
However, the proportion differed significantly by carrier
state: 92 % of physicians provided and/or had knowledge
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of the receipt of genetic counseling for parents in their
practice whose newborns were CFC carriers, while 80 %
of physicians provided and/or had knowledge of the receipt
of genetic counseling for parents in their practice whose
newborns were SCT carriers.
Differences were also seen in counseling location. A
greater proportion of responding physicians provided
counseling in their offices (office-based counseling) to
parents whose infants were SCT carriers compared to
parents whose infants were CFC carriers (41 % vs. 20 %;
p<0.01). Primary care physician (PCP) office counseling
only, without additional counseling elsewhere, was reported
by 20 % of responding physicians for parents whose
newborns were SCT carriers. Only 7 % of physicians
reported providing office-based counseling only for parents
whose newborns were CFC carriers (p<0.01). Physician
demographic characteristics (physician specialty, age, race,
and years in practice) were not associated with office-based
counseling for either carrier state.
Lack of Counseling (Table 2)
A minority of physicians reported that parents whose
newborns were carriers in their practice were not counseled
at all—not in their office or in any other location. A differ-
ence between SCT and CFC was again apparent. While
Table 1 Demographic charac-
teristics (n0298)
aAA African American
bSCD Sickle cell disease
cCF Cystic Fibrosis
*p<0.001 between pediatricians
and family physicians
All respondents Pediatricians Family physicians
% (n) (n0183) (n0115)
% (n) % (n)
Mean years in practice (range) 15 years 15.4 years 14.7 years
(1–42) (1–40) (1–42)
Mean MD age (range) 46.5 years 46.7 years 46.2 years
(29–69) (29–69) (30–68)
MD race
White only 65 (188) 73 (84) 57 (104)
Black only 6 (16) 5 (6) 5 (10)
Other 29 (84) 27 (49) 13 (15)
Multiracial 7 (20) 7 (13) 6 (7)
Practice location
Urban 20 (59) 22 (39) 18 (20)
Suburban 59 (170) 64 (113) 50 (57)
Rural 21 (62) 14 (25) 32 (37)
Practice demographics
> 50 % White 75 (223) 72 (132) 79 (91)
> 50 % AAa 8 (23) 7 (8) 8 (15)
SCDb well care experience
None 30 (89) 18 (32)* 50 (57)*
Extensive (≥ 4 children) 13 (37) 19 (35)* 1 (2)*
CFc well care experience
None 39 (115) 24 (43)* 63 (72)*
Extensive (≥ 4 children) 13 (38) 19 (35)* 2 (3)*
Table 2 Location of counseling by carrier type
None PCP office counseling only Genetic counselor office Specialty center referral PCP office counseling +/− other sitesa
% (n) % (n) % (n) % (n) % (n)
SCT* (n0246) 20 (48) 20 (50) 52 (103) 32 (63) 35 (81)
CFC* (n0206) 8 (16) 7 (14) 66 (122) 49 (91) 18 (37)
a Any parental counseling received in the primary care physician office whether or not additional counseling was provided by a genetic counselor
and/or specialty center
*p<0.01 between SCT and CFC for all 5 columns
Percent adds to>100 % because participants could select more than one option
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20 % of physicians stated that parents whose newborns were
SCT carriers did not receive counseling, only 8 % of physi-
cians reported that parents whose newborns were CFC car-
riers were not counseled. Physicians’ top reasons for lack of
counseling were: a dearth of available genetic counselors,
parental preferences not to be counseled, and that they (the
physician) do not recommend counseling, in that order
(Tables 3). Physicians’ ranking of reasons for lack of paren-
tal counseling were similar in response to both SCT and
CFC genetic counseling. However, the proportions of physi-
cians endorsing each reason were greater for SCT than for
CFC. We were unable to analyze these data further due to
small numbers.
Practice Location and Experience
PCP office counseling was reported by a greater proportion
of physicians in suburban or urban practices than by rural
physicians for parents whose newborns were carriers of
either CFC or SCT. In all practice locations, PCP office
counseling was more commonly reported for parents whose
newborns were carriers of SCT than for parents whose
newborns were carriers of CF (Table 4).
Physicians experienced in providing well care to children
with SCD (caring for four or more children) were signifi-
cantly more likely to counsel parents whose newborns were
SCT carriers in their office than physicians lacking any SCD
well care experience, whether or not additional counseling
was provided elsewhere (63 % vs. 32 %; p00.02). The
association of greater CF well care experience with in-
creased PCP office counseling of parents whose newborns
were CFC carriers was not significant, likely due to the
small numbers of physicians who provide any in-office
counseling to parents whose newborns were CFC carriers.
Non-response
Approximately 18 % of physicians did not respond to ques-
tions concerning counseling of parents whose newborns
were SCT carriers in their practice, and 31 % did not answer
the counseling questions regarding parents whose newborns
were CFC carriers. Non-response was not associated with
physician age, years in practice, or practice location. How-
ever, nearly all (>94 %) of these non-responding physicians
also reported that they had not received a positive newborn
screening test for either SCT (for SCT non-responders) or
CFC (for CFC non-responders) in their practice in the
12 months preceding the survey.
Discussion
In contrast to our prior study, nearly every responding
physician (>95 %) believed that parents whose newborns
are carriers of either condition should be informed of their
child’s status in the newborn period and receive genetic
counseling at that time. While the good news is that 80 %
or more of physicians report that in their practices, parents
whose newborns are carriers are receiving some form of
genetic counseling, the bad news is that 20 % of physicians
report that parents whose newborns are SCT carriers receive
no counseling whatsoever. We also found carrier-related
differences in the locations where counseling is provided.
Primary care physicians were more likely to counsel parents
whose newborns are SCT carriers in their office than parents
whose newborns are CFC carriers.
Our findings raise some questions and concerns.
Newborns with SCT are at risk for rare, but serious health
problems that can begin in late childhood and early adoles-
cence. SCT is associated with painless hematuria, renal
papillary necrosis, and a rare form of renal medullary can-
cer. Hyposthenuria, the inability to produce a concentrated
urine, increases with age, and adds to the risk for exertional
heat illness, rhabdomyolisis, and sudden death with pro-
longed exposure to significant heat and dehydration (Tsaras
et al. 2009). Between 2000–2009, seven student-athletes
with SCT died suddenly. These deaths led the National
Collegiate Athletic Association (NCAA) and the National
Athletic Trainers Association (NATA) to issue guidelines in
2010 for college sports programs that recommend sickle cell
testing for all athletes and modifications to conditioning
programs for athletes with SCT (National Collegiate Athlet-
ic Association 2010). Even though most children with SCT
remain healthy, all are at risk for these complications under
specific conditions. Parents should be aware of the potential
risks and the situations under which they may occur.
It is not known what information is given to parents when
pediatricians and family physicians provide genetic
Table 3 Physicians’ reasons for
not providing counseling or
referrals to parents of newborn
carriers
Percent adds to >100 % because
participants could select more
than one option.
Reason SCT (n048) CFC (n016)
% (n) % (n)
No counselor available 42 (20) 81 (13)
Parents do not want counseling 31 (15) 13 (2)
Physician does not recommend counseling 21 (10) 13 (2)
Other/no reason 15 (7) 13 (2)
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counseling. Primary care physicians may provide parents
with written information from reputable sources such as
the National Institutes of Health and the Sickle Cell Disease
Association of America to parents of newborns with SCT.
However, these pamphlets and brochures are intended to
supplement, not substitute for genetic counseling. Addition-
ally, most primary care physicians lack formal training in
genetic counseling, although they may be aware of the
inheritance patterns and some of the health risks to the child.
Genetic counseling provided by a genetic counselor
includes, but is not limited to, explanations of inheritance
patterns as well as health implications of the carrier state (if
any). The risks to carrier individuals are described in detail
along with behaviors and/or interventions that can minimize
risk. The counselor/geneticist will calculate the parents’ risk
for having a future affected child or carrier and facilitate any
desired testing for parents and family members. While
pediatricians and family physicians may convey some of
this information to parents, it is highly unlikely that all of
this information will be discussed. How much information is
needed in the newborn period, and whether PCP counseling
is adequate to meet parental needs has not previously been
examined and was not the focus of this study.
The differences we found in reported counseling preva-
lence for CFC and SCT are likely due, at least in part, to the
a statewide newborn screening requirement for CF in Mich-
igan, initiated a year prior to our study. Similar to most
states, Michigan uses immunoreative trypsinogen (IRT) test-
ing as the initial newborn screen for CF. An algorithm for
follow-up is included in a letter to the physician of any
infant with a positive test result. Confirmatory DNA and
sweat testing are needed to differentiate children with CF
from normal children with false positive results and carriers.
The algorithm recommends referral to an approved CF
specialty center for the necessary testing and genetic
counseling, but the referral is not mandatory. The contact
information for the center closest to the physician and fam-
ily is included. Nevertheless, physicians are free to order the
sweat test independently without referral to the CF center.
All newborns born in Michigan have been screened for
sickle cell anemia since 1987 (Kleyn et al. 2009b). Newborn
carriers of SCT are identified on the initial screening—
further confirmatory testing is usually unnecessary. The
SCT carrier outreach program receives the names and con-
tact information of newborns identified as carriers of SCT.
Parents receive a letter from the this program informing
them of their infant’s carrier status and offering them further
information and counseling, either in person or by phone
from the outreach program. The contact information of the
closest sickle cell center is also included. The infant’s phy-
sician of record (if known) also receives a letter confirming
the newborn’s carrier status and informing the physician of
the services available from the outreach program for the
infant’s parents.
The SCT and CFC follow-up programs are fairly similar
with regard to the initial physician contact. In both cases, the
infant’s physician is notified about the carrier status (or
likely carrier status) of the infant and is informed of resour-
ces available for further counseling of the parents. Despite
the similarity in initial physician contact and information,
parents whose newborns were SCT carriers were much less
likely to receive any counseling; 20 % of physicians stated
that in their practice, parents whose newborns were SCT
carriers were not counseled at all. We speculate that the
inclusion of a follow-up algorithm for CF may have been
a significant contributor to the higher prevalence of genetic
counseling for parents of newborn CFC carriers, as 85 % of
physicians responded that parents whose newborns were
CFC carriers received some counseling from a genetic coun-
selor/medical geneticist or specialty center, while only 60 %
of physicians reported that parents whose newborns were
SCT carriers received counseling from a genetic counselor/
medical geneticist or specialty center.
In this study, participants were asked whether or not
parents in their practice whose newborns had positive
screens for CFC or SCT received genetic counseling. Those
respondents who stated that the parents did receive genetic
counseling were asked to list all the places where parental
counseling occurred, so it is likely that a portion of parents
of newborns with SCT received counseling from the out-
reach program without the physician’s knowledge. Our
results suggest that the state’s sickle cell carrier outreach
Table 4 Physician practice location and provision of counseling by PCP
Any PCP office counseling SCT (n081) Any PCP office counseling**CFC (n037)
% (n) % (n)
Urban 30* (23) 35** (13)
Suburban 58* (45) 62** (23)
Rural 12* (9) 3** (1)
Counseling given by primary care physician with or without referral to genetic counselor or specialty center
*p00.02 between practice location and SCT status
**p<0.01 between practice location and CFC
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program may not be publicized as well to physicians, may
be understaffed, or some combination of the two.
Physicians need to be aware if and when parents whose
newborns are SCT carriers have received counseling. If the
foundational information has been given, intermittent dis-
cussion and counseling as the child grows to adulthood may
be an effective way to communicate additional information
since the potential risks of SCT increase with age. Pediatri-
cians and family physicians should also be prepared to
properly counsel the parents about the risks of future preg-
nancies. Knowing what prior counseling the parents have
received is part of that preparation.
Study Limitations
Because our data came from physicians’ self-reported be-
havior, we do not know what physicians actually do with
regard to genetic counseling of parents, nor do we know the
content of any office-based counseling they say they pro-
vide. Physicians may also have over-reported counseling
given to parents of newborns with CFC due to social desir-
ability bias with this new program. Although non-response
was not significantly associated with any other measured
variable except experience with a positive newborn screen,
it may have biased our findings in other unknown ways.
Additionally, while the methods used for screening and
follow-up of newborns with sickle cell and cystic fibrosis
or who are carriers of either condition, are similar to those
used in many other states, our sample was drawn from a
single state, which may limit the generalizability of the
findings.
We did not ask physicians about their knowledge of
health risks to persons who are cystic fibrosis or sickle cell
carriers. As such, we cannot know the extent to which the
disparity we found was due to differences in physicians’
perceptions of the risks of the two carrier states.
Conclusions and Research Recommendations
Providing timely and accurate genetic counseling for parents
of newborns who are carriers of SCT or CFC is an important
health service, and one particularly important for parents of
newborns with SCT. The presence of sickle cell trait confers
potential personal health risks that can manifest in child-
hood, not present for persons who are carriers of a cystic
fibrosis mutation. Although the pediatricians and family
physicians in our sample overwhelmingly agreed that
parents whose newborns were carriers of either SCT or
CFC should receive genetic counseling, their subsequent
responses did not support that assertion. When compared
to parents whose newborns were carriers of CFC, parents
whose newborns were carriers of SCT were less likely to
receive counseling from these physicians or were more
likely to only receive office-based counseling.
The data we collected does not allow us to determine the
reason for this apparent health disparity; however the differ-
ences in the information received by the physician between
the two screening programs may be at least partially respon-
sible, along with the fact that one requires a confirmatory
test and the other does not. In addition, many physicians
seemed unaware of the state-supported outreach program for
parents of newborns with SCT. Furthermore, an examina-
tion of primary care physicians’ knowledge of the health
risks to the child with SCT should also be conducted, as our
results may in part be due to misperceptions about the health
significance of having SCT.
While there is consensus that parents whose newborns
are carriers of SCT need genetic counseling, we do not
know whether in-office counseling by the pediatrician or
family physician is adequate to meet parental needs in the
newborn period. Research is needed to examine the content
and quality of the genetic counseling provided by primary
care physicians to parents whose newborns are SCT carriers
to fill this knowledge gap. Considering that approximately
8 % of African American infants will be carriers of SCT,
there should be ample opportunity to develop and test var-
ious methods of providing the necessary information to
determine which counseling method is most effective and
how much information should be provided in the newborn
period, rather than when the child is older. All of this is
complicated by the fact that it is likely the physician who
sees the newborn child will not be the same one who will
see the same child as an adolescent. Given the number of
conditions for which newborns are now screened, new and
alternative methods of providing genetic information to
parents will soon be needed. The lessons learned in creating
and testing new models of counseling parents whose infants
are carriers of SCT can also serve as a prototype for provid-
ing genetic counseling to parents of newborns with other
conditions.
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